EMA Refused: Nezglyal (leriglitazone hydrochloride) — Minoryx Therapeutics S.L.

View source ↗

Summary

The EMA refused to grant marketing authorization for Nezglyal (leriglitazone hydrochloride) for the treatment of adrenoleukodystrophy, under Minoryx Therapeutic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenoleukodystrophy

Drugs mentioned

• Nezglyal (leriglitazone hydrochloride)

Snippet

Status: Refused. Therapeutic area: Adrenoleukodystrophy. MAH: Minoryx Therapeutics S.L.. Decision date: 28/05/2024. Orphan medicine